Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
Polyclonal anti–T-cell IgG binds CD18 (LFA-1 beta) on T cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC, leading to apoptotic/lytic depletion of the bound cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
ATLG antibodies bind CD45 on T cells and deplete them via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional induction of apoptosis.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
Polyclonal antibodies bind T‑cell antigens including CD45/CD45RA, triggering complement-dependent cytotoxicity and Fc-mediated ADCC, with additional apoptosis induction, directly depleting CD45RA+ T cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
YES
DIRECT
Polyclonal anti–T-cell IgG binds CD45RO on T cells and triggers complement-dependent cytotoxicity and Fc receptor–mediated ADCC, inducing apoptosis/lysis.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
NO
INDIRECT
ATLG is a polyclonal anti–T-cell IgG that depletes T cells via complement-mediated lysis, ADCC, and apoptosis after binding T-cell antigens. HLA-DR+ cells (e.g., APCs) are not directly targeted; their activity is reduced indirectly by loss of T-cell help and inflammatory cytokines.